- Home
- LTRN
LTRN
Lantern Pharma Inc.
as 12-23-2024 9:50am EST
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 35.4M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 77.7K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.79 - $11.99 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Lantern Pharma Inc. News
LTRN Breaking Stock News: Dive into LTRN Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?
Insider Monkey
13 days ago
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan
Clinical Trials Arena
14 days ago
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial
Business Wire
14 days ago
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Insider Monkey
16 days ago
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer
Business Wire
20 days ago
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Business Wire
a month ago
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Business Wire
a month ago
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Compare LTRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LTRN Lantern Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.